Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1271026

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1271026

Anti-Cancer MAbS Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Anti-Cancer MAbS Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-cancer mabs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-cancer mabs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anti-cancer mabs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Murine Antibodies; Chimeric Antibodies; Humanized Antibodies; Other Types
  • 2) By Application: Blood Cancer; Breast Cancer; Lung Cancer; Melanoma; Colorectal Cancer; Liver Cancer; Other Applications
  • 3) By End User: Hospitals; Research Institutes; Other End Users
  • Companies Mentioned: Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genmab AS
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab AS, GlaxoSmithKline PLC., Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Roche Holding AG, Gilead Sciences, Bayer HealthCare, and ImmunoGen Inc.

The global anti-cancer MAbS market is expected to grow from $56.27 billion in 2022 to $62.47 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anti-cancer MAbS market is expected to reach $91.12 billion in 2027 at a CAGR of 9.9%.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth and spread.

Noth America was the largest region in the anti-cancer MAbS market in 2022. Asia Paicific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticancer mAbs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of anti-cancer mabs are murine antibodies, chimeric antibodies, humanized antibodies and others. Murine refers to a type of monoclonal antibody (mAb)that are a laboratory-made copy of a single antibody, produced by a single B cell, derived from mice or rats, they are used to bind to a specific antigen. These are used in various applications such as blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer and others and are used in hospitals, research institutes, and others.

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system's own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in 2020, according to research by World Cancer Research Fund International, a UK-based not-for-profit association providing cancer prevention research, estimated 18.1 million active cancer cases globally along with 9.3 million cases in men and 8.8 million in women. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.

Product innovations are a key trend gaining popularity in the anticancer mAbs market. Major companies operating in the anticancer mAbs market are introducing more effective and targeted cancer treatments, such as mAbs drugs to strengthen their position in the market. For instance, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company launched PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a unique monoclonal antibody (mAb) combination treatment for HER2-positive early breast cancer. It is a subcutaneous (under the skin) injection that combines the two mAbs pertuzumab and trastuzumab with the enzyme hyaluronidase. The addition of hyaluronidase, an enzyme that helps to increase the absorption of the mAbs, allows the treatment to be given subcutaneously rather than intravenously.

In May 2021, Exelixis Inc., a US-based genomics-based drug discovery company acquired GamaMabs Pharma SA for an amount of $5 million. With the acquisition of GamaMabs' AMHR2 antibody technology, Exelixis Inc. aims to add an existing drug product portfolio of GamaMabs and related manufacturing cell lines. GamaMabs Pharma SA is a France-based biotechnology focused on developing innovative monoclonal antibodies for the treatment of solid tumors.

The countries covered in the anticancer mAbs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r6323

Table of Contents

1. Executive Summary

2. Anti-Cancer MABs Market Characteristics

3. Anti-Cancer MABs Market Trends And Strategies

4. Anti-Cancer MABs Market - Macro Economic Scenario

  • 4.1. COVID-19 Impact On Anti-Cancer MABs Market
  • 4.2. Ukraine-Russia War Impact On Anti-Cancer MABs Market
  • 4.3. Impact Of High Inflation On Anti-Cancer MABs Market

5. Anti-Cancer MABs Market Size And Growth

  • 5.1. Global Anti-Cancer MABs Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Anti-Cancer MABs Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Anti-Cancer MABs Market Segmentation

  • 6.1. Global Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
  • Other Types
  • 6.2. Global Anti-Cancer MABs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Other Applications
  • 6.3. Global Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals
  • Research Institutes
  • Other End Users

7. Anti-Cancer MABs Market Regional And Country Analysis

  • 7.1. Global Anti-Cancer MABs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Anti-Cancer MABs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Anti-Cancer MABs Market

  • 8.1. Asia-Pacific Anti-Cancer MABs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Anti-Cancer MABs Market

  • 9.1. China Anti-Cancer MABs Market Overview
  • 9.2. China Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Anti-Cancer MABs Market

  • 10.1. India Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Anti-Cancer MABs Market

  • 11.1. Japan Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Anti-Cancer MABs Market

  • 12.1. Australia Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Anti-Cancer MABs Market

  • 13.1. Indonesia Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Anti-Cancer MABs Market

  • 14.1. South Korea Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Anti-Cancer MABs Market

  • 15.1. Western Europe Anti-Cancer MABs Market Overview
  • 15.2. Western Europe Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Anti-Cancer MABs Market

  • 16.1. UK Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Anti-Cancer MABs Market

  • 17.1. Germany Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Anti-Cancer MABs Market

  • 18.1. France Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Anti-Cancer MABs Market

  • 19.1. Eastern Europe Anti-Cancer MABs Market Overview
  • 19.2. Eastern Europe Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Anti-Cancer MABs Market

  • 20.1. Russia Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Anti-Cancer MABs Market

  • 21.1. North America Anti-Cancer MABs Market Overview
  • 21.2. North America Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Anti-Cancer MABs Market

  • 22.1. USA Anti-Cancer MABs Market Overview
  • 22.2. USA Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Anti-Cancer MABs Market

  • 23.1. South America Anti-Cancer MABs Market Overview
  • 23.2. South America Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Anti-Cancer MABs Market

  • 24.1. Brazil Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Anti-Cancer MABs Market

  • 25.1. Middle East Anti-Cancer MABs Market Overview
  • 25.2. Middle East Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Anti-Cancer MABs Market

  • 26.1. Africa Anti-Cancer MABs Market Overview
  • 26.2. Africa Anti-Cancer MABs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Anti-Cancer MABs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Anti-Cancer MABs Market Competitive Landscape And Company Profiles

  • 27.1. Anti-Cancer MABs Market Competitive Landscape
  • 27.2. Anti-Cancer MABs Market Company Profiles
    • 27.2.1. Amgen Inc.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Bristol Myers Squibb Company
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Eli Lilly and Company
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. F. Hoffmann-La Roche Ltd.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Genmab AS
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Anti-Cancer MABs Market

29. Anti-Cancer MABs Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!